Effective September 2022, we welcomed our newly appointed Chief Medical Officer to the AvenCell Leadership Team – Dr. Tapan Maniar.
Tap succeeds Professor Gerhard Ehninger who is moving to our Board of Directors.
For more than a decade, Dr. Maniar has spent the majority of his career in the biotechnology space. Joining Amgen in 2012, Tap worked on multiple late phase programs and commercial launches. At Amgen he served as the Global Development Lead for BLINCYTO® (blinatumomab) (CD19-CD3 bi-specific antibody), which received breakthrough designation from the FDA and led to a historically rapid accelerated approval for relapsed/refractory acute lymphocytic leukemia and subsequent approvals in the EU and globally. Blinatumomab eventually also became the first drug to receive approval for a minimal residual disease setting.
Most recently, Dr. Maniar was Senior Vice President of Clinical Development at Dragonfly Therapeutics where he was the clinical lead for a phase 1 IL-12 program which successfully partnered for $475 million up-front and achieved milestones of an additional $175M before formal handoff to BMS.
Tap received his MD from the University of Pennsylvania, where he was awarded the Lilie M Irk Prize for patient care and where he also completed his medical residency and fellowship in hematology-oncology.
Tap joins AvenCell at a very exciting time and will be instrumental in providing leadership as we continue to advance our development efforts and grow our company.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Phone: +49 351 4466 4500